News
-
-
REGULATED PRESS RELEASE
bioMérieux receives U.S. FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini
bioMérieux receives U.S. FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat Panel Mini, providing fast syndromic testing solutions for healthcare professionals -
-
-
-
-
REGULATED PRESS RELEASE
bioMérieux receives FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), an innovative test to improve the assessment of patients with mild traumatic brain injury
bioMérieux receives FDA 510(k) clearance of VIDAS TBI (GFAP, UCH-L1), a serum-based test to support the assessment of patients with mild traumatic brain injury, improving patient outcomes. The test uses biomarkers to predict absence of acute intracranial lesions -
-
REGULATED PRESS RELEASE
Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisectoral Collaboration to Help Address Antimicrobial Resistance
Malawi Ministry of Health, bioMérieux, and Pfizer collaborate to address antimicrobial resistance in Malawi through infection prevention, control, diagnostics, and surveillance. The initiative aims to combat AMR, a global health threat -
